Cardio Diagnostics Holdings, Inc. (CDIO)
1.76
+0.09
(+5.39%)
USD |
NASDAQ |
Oct 15, 16:00
1.77
+0.01
(+0.57%)
After-Hours: 06:39
Cardio Diagnostics Holdings Research and Development Expense (Quarterly) : 0.1629M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1629M |
| March 31, 2026 | 0.1298M |
| December 31, 2025 | 0.2869M |
| September 30, 2025 | 0.189M |
| June 30, 2025 | 0.0073M |
| March 31, 2025 | 0.0022M |
| December 31, 2024 | 0.0058M |
| September 30, 2024 | 0.0052M |
| June 30, 2024 | 0.0073M |
| Date | Value |
|---|---|
| March 31, 2024 | 0.0108M |
| December 31, 2023 | 0.0075M |
| September 30, 2023 | 0.0387M |
| June 30, 2023 | 0.0123M |
| March 31, 2023 | 0.0867M |
| December 31, 2022 | |
| September 30, 2022 | 0.0032M |
| June 30, 2022 | 0.005M |
| March 31, 2022 | 0.0011M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tenax Therapeutics, Inc. | 12.85M |
| Exicure, Inc. | 0.174M |
| Century Therapeutics, Inc. | 16.98M |
| Absci Corp. | 22.62M |
| Celularity, Inc. | 1.764M |